PTPRC and myelodysplastic syndrome: The 90Yttrium-BC8 anti-CD45 antibody added to a conditioning regimen containing fludarabine and low-dose TBI before allo-HCT has been investigated in a phase I clinical trial in high-risk AML, ALL and MDS [83].